Cargando…

PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma

BACKGROUND: The PD-1 receptor and its ligands PD-L1 and PD-L2 are known to be significantly involved in T-cell regulation. Recent studies suggest that PD-L1 expression in malignant tumors contributes to an immunosuppressive microenvironment and disruption of antitumoral immune response. Drugs target...

Descripción completa

Detalles Bibliográficos
Autores principales:	Müller, Tim, Braun, Martin, Dietrich, Dimo, Aktekin, Seher, Höft, Simon, Kristiansen, Glen, Göke, Friederike, Schröck, Andreas, Brägelmann, Johannes, Held, Stefanie A.E., Bootz, Friedrich, Brossart, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581079/ https://www.ncbi.nlm.nih.gov/pubmed/28881780 http://dx.doi.org/10.18632/oncotarget.17547

Ejemplares similares

PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas
por: Franzen, Alina, et al.
Publicado: (2017)

PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients
por: Goltz, Diane, et al.
Publicado: (2017)

PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma
por: Sailer, Verena, et al.
Publicado: (2016)

Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma
por: Sailer, Verena, et al.
Publicado: (2017)

PITX3 DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinoma
por: Sailer, Verena, et al.
Publicado: (2017)

Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression
por: von Mässenhausen, Anne, et al.
Publicado: (2016)

Nectin-4 is widely expressed in head and neck squamous cell carcinoma
por: Sanders, Christine, et al.
Publicado: (2022)

MERTK as a novel therapeutic target in head and neck cancer
por: von Mässenhausen, Anne, et al.
Publicado: (2016)

Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients
por: de Vos, Luka, et al.
Publicado: (2017)

Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab
por: Schwab, Katjana S., et al.
Publicado: (2018)

MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy
por: Laban, Simon, et al.
Publicado: (2017)

Intragenic DNA methylation of PITX1 and the adjacent long non-coding RNA C5orf66-AS1 are prognostic biomarkers in patients with head and neck squamous cell carcinomas
por: Sailer, Verena, et al.
Publicado: (2018)

CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma
por: Hoffmann, Friederike, et al.
Publicado: (2023)

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
por: Fietz, Simon, et al.
Publicado: (2020)

Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma
por: Holderried, Tobias A. W., et al.
Publicado: (2019)

Sex Determining Region Y-Box 2 (SOX2) Amplification Is an Independent Indicator of Disease Recurrence in Sinonasal Cancer
por: Schröck, Andreas, et al.
Publicado: (2013)

Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors
por: Bao, Yilin, et al.
Publicado: (2021)

Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy
por: Schwab, Katjana S., et al.
Publicado: (2019)

DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients’ survival, immune cell infiltrates, mutational load, and interferon γ signature
por: Sailer, Verena, et al.
Publicado: (2019)

PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations
por: Röver, Lea Kristin, et al.
Publicado: (2018)

Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study
por: Bergheim, Julia, et al.
Publicado: (2018)

Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma
por: Hoffmann, Friederike, et al.
Publicado: (2020)

Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma
por: Fröhlich, Anne, et al.
Publicado: (2020)

PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy
por: Gevensleben, Heidrun, et al.
Publicado: (2016)

CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients
por: Goltz, Diane, et al.
Publicado: (2016)

Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma
por: Fröhlich, Anne, et al.
Publicado: (2020)

Ploidy as a prognostic indicator in end stage squamous cell carcinoma of the head and neck region treated with cisplatinum.
por: Cooke, L. D., et al.
Publicado: (1990)

Reply: Remarks on sentinel node biopsy in head and neck cancer
por: Hoft, S, et al.
Publicado: (2005)

Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites
por: Jung, Maria, et al.
Publicado: (2016)

Baseline immune signature score of Tregs × HLA-DR(+)CD4(+) T cells × PD1(+)CD8(+) T cells predicts outcome to immunotherapy in cancer patients
por: Mispelbaum, Rebekka, et al.
Publicado: (2022)

Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma
por: Rasmussen, Jacob H., et al.
Publicado: (2019)

Development of Hemolytic Anemia in a Nivolumab-Treated Patient with Refractory Metastatic Squamous Cell Skin Cancer and Chronic Lymphatic Leukemia
por: Schwab, K.S., et al.
Publicado: (2016)

Improved PCR Performance Using Template DNA from Formalin-Fixed and Paraffin-Embedded Tissues by Overcoming PCR Inhibition
por: Dietrich, Dimo, et al.
Publicado: (2013)

Oxygen Deprivation Modulates EGFR and PD-L1 in Squamous Cell Carcinomas of the Head and Neck
por: Zahnreich, Sebastian, et al.
Publicado: (2021)

Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck
por: Zandberg, Dan P, et al.
Publicado: (2021)

Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma
por: Ribbat-Idel, Julika, et al.
Publicado: (2021)

HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings
por: Boschert, Verena, et al.
Publicado: (2020)

PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report
por: Nagasaka, Misako, et al.
Publicado: (2016)

PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma
por: Ock, Chan-Young, et al.
Publicado: (2016)

PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma
por: Shen, Bin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pgbuhjufqd6lec1orbhs6its10